JP2008521877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521877A5 JP2008521877A5 JP2007543938A JP2007543938A JP2008521877A5 JP 2008521877 A5 JP2008521877 A5 JP 2008521877A5 JP 2007543938 A JP2007543938 A JP 2007543938A JP 2007543938 A JP2007543938 A JP 2007543938A JP 2008521877 A5 JP2008521877 A5 JP 2008521877A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- pharmaceutical composition
- composition according
- polyunsaturated fatty
- selenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 15
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 239000011669 selenium Substances 0.000 claims description 7
- 229910052711 selenium Inorganic materials 0.000 claims description 7
- HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 claims description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 6
- SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 claims description 5
- 235000021323 fish oil Nutrition 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 229940065287 selenium compound Drugs 0.000 claims 6
- 150000003343 selenium compounds Chemical class 0.000 claims 6
- -1 eicosapentaenoic acid ester Chemical class 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 150000003333 secondary alcohols Chemical class 0.000 claims 2
- 150000003509 tertiary alcohols Chemical class 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 150000003751 zinc Chemical class 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 125000000075 primary alcohol group Chemical group 0.000 claims 1
- 150000003138 primary alcohols Chemical class 0.000 claims 1
- 239000013535 sea water Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 235000011478 zinc gluconate Nutrition 0.000 claims 1
- 239000011670 zinc gluconate Substances 0.000 claims 1
- 229960000306 zinc gluconate Drugs 0.000 claims 1
- 229940050168 zinc lactate Drugs 0.000 claims 1
- 235000000193 zinc lactate Nutrition 0.000 claims 1
- 239000011576 zinc lactate Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0402490A HU227588B1 (hu) | 2004-12-03 | 2004-12-03 | Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény |
| HUP0402490 | 2004-12-03 | ||
| PCT/HU2005/000122 WO2006059169A2 (en) | 2004-12-03 | 2005-11-15 | Antiviral and immunostimulating marine fish oil composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008521877A JP2008521877A (ja) | 2008-06-26 |
| JP2008521877A5 true JP2008521877A5 (enExample) | 2009-05-28 |
| JP4976307B2 JP4976307B2 (ja) | 2012-07-18 |
Family
ID=89985663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543938A Expired - Fee Related JP4976307B2 (ja) | 2004-12-03 | 2005-11-15 | 新規な抗ウイルス性および免疫刺激性の医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9381213B2 (enExample) |
| EP (1) | EP1830861B1 (enExample) |
| JP (1) | JP4976307B2 (enExample) |
| KR (1) | KR101263963B1 (enExample) |
| CN (1) | CN101068540B (enExample) |
| AT (1) | ATE429236T1 (enExample) |
| CA (1) | CA2588195C (enExample) |
| DE (1) | DE602005014142D1 (enExample) |
| DK (1) | DK1830861T3 (enExample) |
| ES (1) | ES2326091T3 (enExample) |
| HU (1) | HU227588B1 (enExample) |
| PL (1) | PL1830861T3 (enExample) |
| WO (1) | WO2006059169A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1800675T4 (pl) * | 2005-12-23 | 2012-02-29 | Nutricia Nv | Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia |
| MX350088B (es) * | 2009-04-29 | 2017-08-25 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| JP5710150B2 (ja) * | 2010-04-08 | 2015-04-30 | 持田製薬株式会社 | 潜伏性感染疾患の再発抑制剤 |
| JP2012149000A (ja) * | 2011-01-18 | 2012-08-09 | Junsei Educational Institution | 免疫賦活剤ならびにこれを含む食品および医薬組成物 |
| EP3248467A1 (de) | 2016-05-25 | 2017-11-29 | Evonik Technochemie GmbH | Verfahren zur herstellung einer zusammensetzung enthaltend omega-3-fettsäure-l-lysin-salze |
| CN114072155A (zh) * | 2019-04-01 | 2022-02-18 | 豪恩·西蒙·夏 | 用于癌症免疫疗法的组合物和方法 |
| AU2021324673B2 (en) * | 2020-08-10 | 2025-07-24 | Houn Simon Hsia | Compositions and methods for treating viral infection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU209973B (en) | 1988-03-09 | 1995-01-30 | Biorex Kutato Fejlesztoe Kft | Process for production of antiviral and immunstimular pharmaceutical composition |
| HU199775B (en) * | 1988-03-09 | 1990-03-28 | Nagy Peter Literati | Process for production of formed by fatty acids salts of amin acids and medical compositions containing them |
| HU210122B (en) * | 1988-03-23 | 1995-02-28 | Biorex Kutato Fejlesztoe Kft | Process for production of composition against thromboembolytic conditions of circulating system and heart |
| IT1264987B1 (it) * | 1993-12-14 | 1996-10-17 | Prospa Bv | Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono |
| IT1274734B (it) * | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| EP0891771A1 (en) * | 1997-07-08 | 1999-01-20 | Health Now, Inc. | Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases |
| KR100587551B1 (ko) * | 1997-12-10 | 2006-06-08 | 싸이클로스포린 테라퓨틱스 리미티드 | 오메가-3 지방산 오일을 함유하는 약학 조성물 |
| AT412758B (de) * | 2000-06-05 | 2005-07-25 | Vis Vitalis Lizenz & Handels | Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen |
| ES2386782T3 (es) * | 2002-03-08 | 2012-08-30 | Philera New Zealand Limited | Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada |
-
2004
- 2004-12-03 HU HU0402490A patent/HU227588B1/hu not_active IP Right Cessation
-
2005
- 2005-11-15 DE DE602005014142T patent/DE602005014142D1/de not_active Expired - Lifetime
- 2005-11-15 JP JP2007543938A patent/JP4976307B2/ja not_active Expired - Fee Related
- 2005-11-15 AT AT05808584T patent/ATE429236T1/de not_active IP Right Cessation
- 2005-11-15 ES ES05808584T patent/ES2326091T3/es not_active Expired - Lifetime
- 2005-11-15 CA CA2588195A patent/CA2588195C/en not_active Expired - Fee Related
- 2005-11-15 DK DK05808584T patent/DK1830861T3/da active
- 2005-11-15 US US11/792,247 patent/US9381213B2/en not_active Expired - Fee Related
- 2005-11-15 CN CN200580041636XA patent/CN101068540B/zh not_active Expired - Fee Related
- 2005-11-15 KR KR1020077014591A patent/KR101263963B1/ko not_active Expired - Fee Related
- 2005-11-15 PL PL05808584T patent/PL1830861T3/pl unknown
- 2005-11-15 WO PCT/HU2005/000122 patent/WO2006059169A2/en not_active Ceased
- 2005-11-15 EP EP05808584A patent/EP1830861B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540394A5 (enExample) | ||
| AU593317B2 (en) | Pharmaceutical compositions | |
| JP2013508296A5 (enExample) | ||
| EP3157936B1 (en) | Mineral amino-acid complexes of active agents | |
| RU2015136190A (ru) | Композиции и способы, используемые для повышения и поддержания кетоза | |
| CN87104644A (zh) | 广谱杀病毒剂 | |
| CA2607247A1 (en) | .alpha.-substituted dha derivatives | |
| WO2009091538A3 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
| JP2021525787A5 (enExample) | ||
| JP2011503057A5 (enExample) | ||
| JP2018515463A5 (enExample) | ||
| JP2010509204A5 (enExample) | ||
| JP2016501248A5 (enExample) | ||
| JP2024544415A5 (enExample) | ||
| CA2000398A1 (en) | Triglycerides, nutritional composition comprising such triglycerides, and use of the nutritional composition for nutrition | |
| CA2411568A1 (en) | Compositions for the therapy of dementias | |
| JP4976307B2 (ja) | 新規な抗ウイルス性および免疫刺激性の医薬組成物 | |
| JP2018510206A5 (enExample) | ||
| RU2017137960A (ru) | Применение тиаоксосоединений для уменьшения содержания аро сз | |
| JP2020083879A (ja) | 液体口腔用組成物 | |
| JP2007519603A (ja) | 血管保護物質の組合せおよびそれらを含む製剤 | |
| JPH0759540A (ja) | アラキドン酸含有健康食品 | |
| JP3585306B2 (ja) | 防腐防黴剤 | |
| JPS63216818A (ja) | う蝕予防剤 | |
| CA2427289A1 (en) | Fat composition and hexacosanoic acid depressant for oral or enteral administration |